August 20, 2020 07:34 AM EDTUpdated 11:15 AM

Covid-19 roundup: Pfizer/BioNTech spell out PhIII priority; Legal experts urge FDA to refrain from vaccine EUAs

Max Gelman

Senior Editor

Amber Tong

Milder side effects among the elderly were critical in Pfizer and BioNTech’s choice of vaccine candidate to send into Phase III testing, the companies revealed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 roundup: Pfizer/BioNTech spell out PhIII priority; Legal experts urge FDA to refrain from vaccine EUAs

Max Gelman

Senior Editor

Amber Tong

Sign up to read this article for free.

Pfizer looking to sell hospital drugs unit — reports

AstraZeneca CEO reaffirms commitment to China following executive's detention

'Expertise is a real thing': FDA commissioner warns of political risk to agency

Merck, AstraZeneca tout Phase 3 win for cancer-turned-rare disease drug

Novartis pays $150M upfront to Schrödinger in new drug deal, ramps up software use

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

Covid-19 roundup: Pfiz­er/BioN­Tech spell out PhI­II pri­or­i­ty; Le­gal ex­perts urge FDA to re­frain from vac­cine EUAs

Senior Editor

Sign up to read this article for free.

Covid-19 roundup: Pfizer/BioNTech spell out PhIII priority; Legal experts urge FDA to refrain from vaccine EUAs